Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates
08:41am, Thursday, 13'th May 2021
Curis Inc (NASDAQ: CRIS) stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2021 Results - Earnings Call Transcript
10:32pm, Wednesday, 12'th May 2021
Curis, Inc. (CRIS) CEO Jim Dentzer on Q1 2021 Results - Earnings Call Transcript
Curis Reports First Quarter 2021 Financial Results
04:01pm, Wednesday, 12'th May 2021
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its
CRIS Stock: Over 55% Increase Intraday Explanation
01:27pm, Wednesday, 12'th May 2021
The stock price of Curis, Inc. (NASDAQ: CRIS) increased by over 55% during intraday trading. This is why it happened.
Why Curis (CRIS) Shares Are Surging Today?
12:59pm, Wednesday, 12'th May 2021
Curis Inc (NASDAQ: CRIS) shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-ri
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced t
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
09:46am, Wednesday, 12'th May 2021
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021
08:00am, Wednesday, 05'th May 2021
LEXINGTON, Mass., May 5, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know
03:47pm, Tuesday, 04'th May 2021
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
08:00am, Monday, 19'th Apr 2021
LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to a
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 07'th Apr 2021
LEXINGTON, Mass., April 7, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced
Steven Cohen Dives Deeper Into Health Care
04:53pm, Tuesday, 23'rd Mar 2021
Steven Cohen ( Trades , Portfolio ) has revealed a new buy into Prometheus Biosciences Inc. (NASDAQ:RXDX) alongside an addition to his position in Curis Inc. (NASDAQ:CRIS) according to GuruFocus Real-
What's Happening With CRIS Stock, SRGA Stock And PDD Stock Wednesday?
09:05am, Wednesday, 17'th Mar 2021
One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.
Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2020 Results - Earnings Call Transcript
10:27pm, Tuesday, 16'th Mar 2021
Curis, Inc. (CRIS) CEO Jim Dentzer on Q4 2020 Results - Earnings Call Transcript
Recap: Curis Q4 Earnings
04:24pm, Tuesday, 16'th Mar 2021
Shares of Curis (NASDAQ:CRIS) decreased after the company reported Q4 results. Quarterly Results Earnings per share increased 57.69% year over year to ($0.11), which missed the estimate of ($0.09).
